#United States #New York #Class Action #Pomerantz Law #PROCEPT BioRobotics

Overview of the Class Action Lawsuit

On September 3, 2026, Pomerantz LLP announced the initiation of a class action lawsuit against PROCEPT BioRobotics Corporation (ticker: PRCT). This lawsuit is primarily directed at shareholders who faced financial losses due to alleged illegal practices by the company and its executives. Investors who acquired shares within the specified period are advised to take note of important deadlines associated with the lawsuit.

Background of PROCEPT BioRobotics

PROCEPT BioRobotics is known for its innovative approaches in the medical robotics sector, specifically focusing on surgical instruments. However, the company has recently faced scrutiny after a series of disappointing sales performance reports. On August 6, 2025, PROCEPT publicly shared second fiscal quarter results, revealing substantially lower than expected handpiece sales, creating a ripple effect in their stock prices. The announcement indicated only about 12,750 units sold in the United States, with projections for the future quarter suggesting only a marginal improvement.

Impact on Shareholders

The aftermath of such announcements reflected negatively on the company's stock. Following the disappointing sales report, the stock experienced a staggering 16% decline over a mere two-day trading window. Financial forecasts adjusted downward, intensifying investor concerns, especially when then-CEO Reza Zadno stated plans to eliminate the Chief Commercial Officer's role to boost operational performance. This move was another alarm bell ringing for investors who felt the uncertainty surrounding the company's leadership.

On November 4, 2025, the situation did not improve, as PROCEPT's third quarter results again fell short of expectations, with sales reported at only 13,225 handpieces, missing previous guidance. Further complicating matters, PROCEPT announced a reduced sales target, indicating potential issues in inventory management and overall business strategy. This news triggered an additional 10% plunge in stock value.

Continued Decline and Mismanagement Claims

The situation escalated when, on February 25, 2026, PROCEPT disclosed alarming fourth fiscal quarter results, indicating a significant decrease in quarterly handpiece sales from the third quarter, dropping to 9,400 units. More than just disappointing sales figures, the announcement revealed a failure in managing inventory levels, resulting in excess inventory approaching 10,000 units. This not only confirmed mismanagement concerns but also contributed to yet another drop in the stock price, this time by over 18% in just two days.

Legal Clarity for Investors

Pomerantz LLP is urging affected investors to act promptly. Those who purchased PROCEPT BioRobotics securities during the designated class period can submit their request to the court before September 22, 2026, to assume the role of Lead Plaintiff in this lawsuit. Interested parties can seek further information through the firm’s website or by contacting the firm directly.

About Pomerantz LLP

Founded by Abraham L. Pomerantz, recognized as a pioneer in securities class action litigation, Pomerantz LLP has built a robust reputation over the past 85 years in fighting for the rights of investors impacted by corporate misconduct. Their track record of recovering millions for class members exemplifies their dedication and expertise in navigating complex legal landscapes involving corporate fraud and breaches of duty. For additional details about joining the class action, visit www.pomerantzlaw.com or reach out to Danielle Peyton via email.

With the evolving situation surrounding PROCEPT BioRobotics and the spotlight on their corporate practices, investors are encouraged to stay informed and consider their legal options carefully.